Signia announced the launch of its newest lineup of Motion Charge&Go X hearing aids, which includes the Motion Charge&Go SP X – said to be the “first-ever rechargeable super power hearing aid that delivers uncompromised hearing with up to 61 hours of run-time per charge.” The Motion Charge&Go SP X, and its rechargeability, helps “ensure that even individuals with severe-to-profound hearing loss can enhance their human performance through improved hearing in every situation.”
This joins two other all-new Motion hearing aids – Motion Charge&Go P X and Motion Charge&Go X – to complete Signia’s latest lineup of Motion Charge&Go behind-the-ear (BTE) hearing solutions that are said to address “all levels of hearing loss.”
“Those with moderate to severe hearing loss depend heavily on their hearing aids – and not just for catching the total at the grocery checkout line or the specials at a restaurant, but for the real connections and sounds that give life meaning,” said Dr Tish Ramirez, Signia’s Vice President of Professional Relations and Product Management. “Signia Motion X delivers industry-best rechargeability and connectivity to ensure wearers stay better connected to their world without any limitations. Motion X hearing aids don’t just provide better hearing, they help provide a better life.”
Motion Charge&Go SP X is said to have up to 61 hours per charge, according to Signia, and is “the world’s most powerful rechargeable hearing aid.” The Motion Charge&Go P X offers up to 30 hours per charge, while the Motion Charge&Go X offers up to 24 hours per charge.
Signia Motion Charge&Go X: A new era in hearing technology
Signa’s “first-of-its-kind acoustic-motion sensor technology” is said to recognize one’s movements and adjusts sounds accordingly to ensure hearing in any situation is as precise and personalized as possible. Signia’s world’s-first OVP is a cutting-edge technology that processes the wearer’s voice separately from other sounds, leading to higher user satisfaction with the sound of their own voice.[1]
The Signia app provides access to hearing aid controls, streaming capabilities, tinnitus therapy, the Signia Assistant for a more personalized listening experience, and 24/7 digital support, Signia Telecare for remote care support, Signia Face Mask Mode for better speech understanding through masks, and much more.
Furthermore, the Xperience fitting (XFit) strategy helps offer a choice between more linear and more compressive gain settings for those with moderate-to-profound hearing loss. With the Dynamic Soundscape Processing slider, the wearer can “easily find a preferred balance of sound for best performance.” Additionally, the AI-based Signia Assistant helps allow the wearer to be more involved in actively shaping the sound quality of their own hearing aid.
All three models of Motion Charge&Go X offer Li-ion charging, Bluetooth connectivity, and an optional telecoil. They are available in all performance levels and can be ordered with an optional charger upgrade that includes a UV Dry&Clean function.
“Signia has invested heavily in developing first-of-its-kind, industry-leading technologies – across rechargeability, connectivity, speech intelligibility, and more,” said Ramirez. “However, this investment has been made with the sole aim of creating hearing solutions that prove people don’t have to be limited by their hearing loss – and that with one’s hearing restored, there’s nothing holding them back from performing their best.”
https://honiton-hearing.co.uk/wp-content/uploads/2020/03/Honiton-hearing-Devon.jpg480640adminhttps://honitonnew.leecurran.co.uk/wp-content/uploads/2018/03/honitonhearinglogo.pngadmin2021-03-17 17:57:072021-03-17 17:57:07Signia Launches Motion X Hearing Aids
By Laura Winther Balling, PhD, Oliver Townend, BSc, and Dana Helmink, AuD
Sound quality plays a key feature for overall hearing aid satisfaction as well as in everyday moments of real-life hearing. A large international survey of hearing aid users confirms the importance of sound quality, showing higher satisfaction with the WIDEX MOMENT™ hearing aids for overall sound quality, for specific situations of real-life use and for hearing aid users’ ability to participate in daily life.
As one of the major global hearing aid manufacturers, Widex has a long history of focusing on sound quality, designing all signal processing with the aim of achieving the best and most natural sound quality possible. For example, True Input Technology, with a linear transfer function up to 113 dB SPL and a linear input dynamic range of 108 dB SPL, was groundbreaking when launched,1 as was Variable Speed Compression, which offers the benefits of both slow and fast-acting compression.2
Most recently, WIDEX MOMENT™ launched with the focus on sound quality expressed in two main features:
TruAcoustics™ is an intelligent algorithm by which the acoustics in the individual ear canal is integrated in the parameter settings of the hearing aid, so the output at the eardrum is exactly right for the individual ear canal with the specific earware choice.3
Widex PureSound™ drastically reduces hearing aid delay and eliminates the delay-based distortions which are characteristic of other digital hearing aids.4
Innovations like these improve the sound quality in clearly audible ways and result in sound quality preferences in studies, such as the one reported by Balling et al.4 However, it is also an important assumption of the Widex design philosophy that good sound is not an isolated quality but a means to achieving higher hearing aid satisfaction across many situations in real life. With this broader view of sound quality, it is arguably the most important parameter for hearing aid satisfaction, along with speech understanding (especially in noise).
For these reasons, the survey reported below focused on satisfaction with sound quality in itself, as well as the experience in diverse situations of real-life hearing with Widex MOMENT hearing aid.
Survey Method
Our survey included 101 experienced hearing aid users recruited at local hearing clinics in 7 countries (US, Canada, China, Germany, France, Portugal, UK). They all wore the MOMENT mRIC R D rechargeable hearing aids and rated their satisfaction with them in comparison to their own existing hearing aids, which were from all major brands. Respondents were 60% male with a median age of 66 years (range 18-88). Close to half (45%) were work active, and they had a median of 6 years’ hearing aid experience (range 1-59 years).
Respondents fell into two groups: 39 of them had mild-to-moderate hearing losses going from 40 dBHL at low frequencies to 70 dBHL at high and had as their primary program PureSound™, which is particularly suitable for open fits and milder losses. The other 62 respondents had hearing losses up to 80 dB HL across frequencies (the mRIC M-receiver fitting range) and were fitted with the Universal program as their primary program. The MOMENT hearing aids were fitted with the ear tip recommended in the Compass GPS fitting software.
The survey used a cross-over design where respondents started a 7-week survey period by rating their satisfaction with their own existing hearing aids before being fitted with the MOMENT hearing aids and wearing them for 3 weeks. After 3 weeks, they rated their satisfaction with the MOMENT devices, before switching back to their own hearing aids, wearing those for 2 weeks and rating them at Week 6. For the final 2 weeks of the survey, respondents wore MOMENT and filled in a final set of questions about those at Week 7. This resulted in two ratings for own hearing aids (at Weeks 0 and 5) and two for MOMENT (at Weeks 3 and 7).
The questionnaires were filled in online using SMART-TRIAL software, using a format inspired by the MarkeTrak surveys,5 where respondents rate their satisfaction with their hearing aids on a 7-point scale ranging from “Very dissatisfied” (a rating of 1) to ‘Very satisfied’ (a rating of 7). Following the MarkeTrak approach, respondents who gave ratings in the top-3 satisfaction categories may be classified together as being “satisfied.” We asked questions about satisfaction both in general and in specific real-life situations.
The responses show that people are reasonably satisfied with their own hearing aids at the beginning of the survey period, but once they try the MOMENT hearing aids, their ratings of their own hearing aids in many cases become significantly lower. This in itself is evidence in favor of the MOMENT devices. However, the more interesting direct comparison is between the ratings of own hearing aids in Week 5 and MOMENT in Week 7, where respondents have had the most time to form an opinion about the new hearing aids.
We also estimated the age of the respondents’ own hearing aids based on the launch date of the device. Interestingly, we found no significant effects of this variable, indicating that the MOMENT advantages that we observe throughout are not simply explained by the contrast between older own hearing aids and new MOMENT devices, but by a genuine preference for the MOMENT sound.
Unless otherwise indicated, statistical testing of results was done using mixed-effects models that take into account the crucial fact that we have multiple responses per person. The significance levels for the relevant contrasts between own and MOMENT hearing aids are all below 0.0001, which means that potential concerns about repeated testing are unfounded.
Sound Quality Across Situations
As we would expect given the Widex design focus, the responses show a solid sound quality advantage for the MOMENT hearing aids, with significantly higher satisfaction for MOMENT than for own hearing aids (p < 0.0001). Looking at the average ratings plotted in the left panel of Figure 1, there is a 1-point advantage for MOMENT, with the average rating “Satisfied” for MOMENT and “Somewhat satisfied” for own hearing aids. Examining the distribution of answers in the right panel of Figure 1, we see many more “Very satisfied” and “Satisfied” MOMENT users. In total, considering the top-3 satisfaction categories, 91% of respondents are satisfied with the MOMENT sound quality.
Figure 1. Ratings of satisfaction with sound quality. The left panel shows mean ratings of satisfaction with sound quality as filled circles, with the whiskers representing ±1 standard deviation (SD) around the mean. The right plot shows ratings of own hearing aids in Week 5 and of MOMENT hearing aids in Week 7 of the survey.
An intriguing question is which aspects of sound and hearing aid use influence these high-satisfaction sound quality ratings. This is a complex issue that this survey cannot fully address, but it is informative to look at which other questions are correlated with sound quality satisfaction. In Table 1, such correlations are listed for the ratings of MOMENT at the end of the survey period. They are all strong correlations ranging between 0.522 to 0.698, and although there is some variation between individual situations, the correlations are all highly significant and of similar size. These correlations do not, of course, indicate causation but do suggest that sound quality plays a similar role across different situations.
Table 1. Spearman Rho correlations between sound quality satisfaction and satisfaction in specific situations for WIDEX MOMENT. (Notations: *** indicates significance at the p<0.001 level; a) Speech-in-noise situations; b) Outdoor situations; c) Listening through devices.
Another way of assessing the impact of sound quality on everyday satisfaction with hearing aids is analyzing the average satisfaction across the specific situations listed in Table 1 (excepting satisfaction with soft and loud sounds, which are not specific situations). A regression model shows that satisfaction with sound quality is a highly significant predictor of mean satisfaction across situations, accounting for more than 50% of the variance in satisfaction across situations (R2 = 0.51).
Sound Quality and Naturalness
In addition to the different listening situations, Table 1 also lists respondents’ agreement with the statement “I find that the sound is natural with the MOMENT hearing aids” on a 7-point scale. This shows one of the highest correlations with sound quality satisfaction, which means that those hearing aid wearers who are highly satisfied with the sound quality also perceive the sound as more natural.
In addition, naturalness ratings show a very similar pattern across weeks to sound quality satisfaction, as illustrated in Figure 2. Again, we see approximately a 1-point difference between the ratings of own and MOMENT hearing aids, and many more who “Agree” or “Strongly agree” that the sound of MOMENT is natural.
Figure 2. Ratings of naturalness of sound, with the left panel showing mean ratings per week and the right panel showing ratings for own hearing aids in Week 5 and for MOMENT in Week 7.
Satisfaction in Everyday Situations
As seen in Table 1, the survey included questions on a wide range of everyday situations. In Figure 3, these are grouped into four different more general categories, showing the distribution of ratings in Week 5 (own hearing aids) and Week 7 (MOMENT hearing aids).
Figure 3. Histograms showing distribution of ratings in Weeks 5 (own hearing aids) and 7 (MOMENT hearing aids).
The top-left panel shows the satisfaction with conversations in quiet, assessed by a single question. Level of satisfaction is generally high, as we would expect for this relatively easy listening environment. However, although the baseline is already high, the MOMENT ratings are still higher, with the most frequent response being “Very satisfied” and the difference to own hearing aids being highly significant (p < 0.0001).
Speech-in-noise ratings are shown in the top-right panel, based on a mean across questions on satisfaction in restaurants and with conversations in noise and during transport. These tend to be difficult situations for hearing aid users, which is also clear if we compare the general level of satisfaction with speech in quiet. This makes the significant advantage for MOMENT (p < 0.0001) all the more noteworthy: the most frequent mean rating for these questions is clearly in the “Satisfied” category for MOMENT, whereas ratings for own hearing aids are more spread out, with “Somewhat dissatisfied” as the most frequent. If we compare the own-vs-MOMENT hearing aid ratings per respondent, five times as many respondents are more satisfied with the MOMENT hearing aids compared with their own: 74% of respondents are more satisfied with MOMENT, 12% more satisfied with their own, and the remaining 14% give the same ratings to both.
The bottom left panel illustrates mean ratings in outdoor situations, again with a markedly differently distribution of ratings for own and MOMENT hearing aids (p < 0.0001). Part of the explanation for the MOMENT advantage could be that respondents experience the sound of MOMENT as more natural, something that is likely to play a larger role outdoors.
The final panel of Figure 3 represents the frequent listening situations where sound comes from a device, with TV likely being the most frequent for most people, but also telephone and music. As for conversations in quiet, the general level of satisfaction is higher here than for more difficult listening situations, but the MOMENT advantage remains, with a significant difference to own hearing aids (p < 0.0001). Collectively, the four types of situations illustrated in Figure 3 give a comprehensive view of the everyday lives of hearing aid users, and across all these situations MOMENT shows a solid advantage.
Participation in Daily Life
A common problem for people with hearing loss, reported both scientifically6,7 and by hearing aid users and their relatives to HCPs all over the world, is the difficulty of participating in everyday life. Therefore, the survey included a question inspired by the International Outcome Inventory for Hearing Aids (IOI-HA)8: “How satisfied are you with your ability to participate effortlessly in everyday life with [your own hearing aids/the WIDEX MOMENT hearing aids]?” The ratings for this question are shown in Figure 4, where both plots illustrate a similar 1-point MOMENT advantage that was also seen previously (p < 0.0001). An interesting statistic is how many people are satisfied (in the top-3 categories) with their ability to participate in everyday life; this number is 69% for own hearing aids but 90% for MOMENT. Conversely, only 6% of respondents indicate dissatisfaction with participation when wearing MOMENT, while the corresponding number is 20% for own hearing aids, in spite of the fact that the MOMENT devices are new to the respondents and they cannot be expected to be completely habituated to them yet.
Figure 4. Ratings of ability to participate in everyday life, with the left panel showing mean ratings per week and the right panel showing ratings for own hearing aids in Week 5 and for MOMENT in Week 7.
Overall Satisfaction
Finally, a question about overall satisfaction examines how all these different elements of real-life hearing come together in the respondents’ entire experience of wearing the MOMENT hearing aids, compared with their own. The responses to this question were tested in the same way as previous results, showing significantly higher ratings (p < 0.0001) for MOMENT than own hearing aids. The left panel in Figure 5 is a particularly clear example that respondents’ ratings of their own hearing aids change when they have tried MOMENT, as evidenced by the lower ratings in Week 5 compared to Week 0. More generally, Figure 5 confirms the MOMENT advantage that has also been clear in the more detailed questions, with the most frequent overall response to the MOMENT hearing aids being “Very satisfied.”
Figure 5. Ratings of overall satisfaction, with the left panel showing mean ratings per week and the right panel showing ratings for own hearing aids in Week 5 and for MOMENT in Week 7.
The Importance of Sound Quality in Real Life Hearing Aid Use
https://honiton-hearing.co.uk/wp-content/uploads/2021/03/Widex-Hearing-aids-Honiton-Devon.png412412adminhttps://honitonnew.leecurran.co.uk/wp-content/uploads/2018/03/honitonhearinglogo.pngadmin2021-03-03 10:30:222021-03-03 10:30:22Widex Moment
Phonak announced the launch of the second generation of Roger Focus, the ear-level receiver that allows “children, teens, and adults to hear a speaker’s voice via any Roger microphone.” Research has shown that speech recognition in noise is significantly improved for children with unilateral hearing loss 1,2, autism spectrum disorder 3,4 , and auditory processing disorder 5 when using Phonak remote microphone technologies like Roger Focus II compared to no technology.
Potential applications for Roger Focus II include:
Unilateral hearing loss (UHL) UHL affects 1-3% of school children 6,7 and left untreated, can impact a child’s behavior, social engagement, and anxiety levels.8-10 Emerging research shows that when using Roger Focus II, children with UHL have 53 percentage-points better speech understanding in noise at five meters distance compared to their normal hearing peers and even show significant improvement in quiet environments compared to no technology.11
Autism spectrum disorder (ASD) Some children on the autism spectrum with normal hearing have “functional hearing loss,” which is loosely defined as a hearing loss with no natural or physiological cause.12 In other words, these children have impaired auditory filtering that makes it difficult to hear, function, and complete tasks in the presence of background noise.8 Parents reported improved listening in children with ASD and teachers reported that classroom attentiveness, behavior, and listening improved in children with ASD when using Phonak remote microphone technology like Roger Focus II. 13-15
Auditory processing disorder (APD)
Children with APD may also experience functional hearing loss despite normal hearing and may have difficulties with spatial sound processing and word discrimination. This can result in poorer behavior, attention, and concentration7 while leading to negative psychosocial effects like social withdrawal, difficulty with interpersonal relationships, and increased anxiety.16 Speech understanding in noise is improved significantly in children with APD when using Phonak remote microphone technology like Roger Focus II compared to no technology, according to Phonak. Meanwhile, students report improvement in anxiety, depression, and interpersonal relationships.
“Roger Focus II was developed to help children overcome the challenges of hearing over distance and in background noise so that they can focus on what matters,” said Angela Pelosi, director of global audiology at Phonak. “As a leading innovator of world-class pediatric hearing solutions, it’s critically important that we provide children with unilateral or functional hearing loss the confidence that they can fully participate in everyday activities—and the Roger Focus II does just that.”
The new Roger Focus II is available in a new lithium-ion rechargeable option or a traditional zinc-air battery featuring a “tamper-proof” battery door. According to Phonak, it received an IP68-rating for water and dust resistance and has new coupling options to fit even smaller ears than its predecessor. The rechargeable version comes in ten assorted colors and offers up to 20 hours of battery life on a full charge.
Roger Focus II is intended for children over three years old and is available to order today via licensed hearing care professionals in the US and other select markets.
https://honiton-hearing.co.uk/wp-content/uploads/2021/02/Phonak-hearing-aids-Devon.png600600adminhttps://honitonnew.leecurran.co.uk/wp-content/uploads/2018/03/honitonhearinglogo.pngadmin2021-02-23 10:59:082021-02-23 10:59:08Phonak Launches Roger II Focus Ear-Level Receiver
Phonak, a global provider of hearing solutions, announced Naída Paradise, the power hearing aid that “gives people with severe-to- profound hearing loss the power, sound quality, and wireless connectivity they need to connect with everything around them.” Now in its seventh generation, Naída Paradise is said to be “14% smaller, 27% lighter1, and further improves upon the hearing performance that wearers expect from Phonak.” This includes “powerful sound, industry-leading connectivity, and soon a new custom program memory feature with the new myPhonak 5.0 app.”
Phonak Naida Paradise and Roger On
Naída Paradise features a powerful double receiver that delivers up to 141 dB of peak gain in the UP model and up to 130 dB in the rechargeable model, according to Phonak. It’s powered by the new PRISM sound processing chip and features AutoSense OS 4.0 for “a host of premium features that work together seamlessly.” For example, the hearing aids can “automatically enhance soft speech in quiet places or reduce noise in loud environments.” A built-in accelerometer detects movement and automatically steers the microphones to improve listening on-the-go.2
Phonak Naida Paradise
Naída Paradise helps eliminate connectivity barriers that previously existed for consumers who needed more power. With Phonak universal connectivity, wearers can wirelessly stream audio directly into both hearing aids from virtually any smartphone, TV, laptop, tablet, eBook, and more. Phonak Paradise technology helps allow two active Bluetooth connections at the same time, so wearers can stay connected to their smartphone and their video chat without having to manually switch back and forth.
In addition to universal Bluetooth connectivity, Naída Paradise hearing aids are also equipped with RogerDirect. This means wearers can also receive the Roger remote microphone signal with no additional accessory required. Launched in 2013, Roger™ technology is “proven to boost hearing performance in loud noise and over distance.” In fact, hearing aid wearers who receive the Roger signal have better speech understanding in noise and over distance than people with normal hearing.3 Some Roger microphones and receivers have also been shown to help users understand up to 61% more speech in a group conversation in 75dBA of noise than using hearing aids alone.4
Universal Bluetooth connectivity coupled with on-board microphones means Naída Paradise wearers can use their hearing aids as wireless headsets for hands-free calls. A new Tap Control2 feature allows users to double tap on their ear to accept or end a call, or pause or resume streaming. A tap on the other ear gives access to smartphone voice-assistants like Siri or Google Assistant.
“Naída has a long-lasting history of delivering power without sacrificing sound quality, so we knew that we needed to deliver an outstanding product to our wearers who depend so heavily on their devices,” said Jon Billings, Vice-President Phonak Marketing. “With Naída Paradise, we’re making history again by giving those with severe forms of hearing loss access to next-level, powerful sound with industry-leading connectivity.”
In late spring, the myPhonak app’s 5.0 update will include the myPhonak Memory feature. It helps allow consumers to save a custom program from the app to the hearing aids, access the last-used custom program using the hearing aid’s multi-function button, or access other custom programs via the app.
Phonak is also preparing for the newest member of the Roger family with the debut of Roger On. The new Roger On remote microphone will feature MultiBeam 2.0 technology and an “improved pointing mode that allows the user to zoom into a speaker by simply pointing.” Roger On will be compatible with most hearing aids and cochlear implants and will be able to stream a variety of audio content.
The new Phonak Naída Paradise is available for pre-order by licensed hearing care professionals in the US and other select markets and will begin shipping in late February. The myPhonak 5.0 app featuring myPhonak Memory feature as well as the new Roger On microphone will be introduced in the US and other select markets in late spring.
For US hearing care professionals to learn more and to pre-order: https://www.phonakpro.com/us/en/campaign/naida.html.
Source/Reference
1 Naída P UP with RogerDirect compared to Naída B UP + external Roger receiver.
2 In the Phonak power BTE portfolio, only Naída P-PR comes with motion sensor technology, including Tap Control.
When you hear the word “earwax”, you might immediately think YUCK! But, did you know that earwax actually plays an important role in the health of your ear? I’d like to share some facts about earwax and the part it plays in a healthy ear.
1. Earwax is not YUCK at all
In fact, earwax is a requirement of a healthy ear canal. It is a product of two glands that are in the ear canal: sweat glands (known as “apocrine sweat glands”) and cerumen glands (known as “sebaceous glands”). Without earwax, ear canals would be dry and itchy. As a result, the ear canals would be more susceptible to scrapes and cuts from scratching.
2. The ear is designed to naturally rid itself of earwax
The skin cells in the ear canal are “migratory” skin cells. New skin cells in the ear canal are formed near the ear drum and then tend to work their way outward over time, carrying earwax and debris with them. These are called “migratory cells” because they migrate their way from inside the ear canal to outside the ear canal.
3. Earwax problems are less common than you think
Thanks to the migratory process of the ear canal, a true “earwax problem” is not as common as you might think. In fact, those who are most at risk for impacted earwax are (1) older adults (2) hearing aid users (3) those who use cotton swabs. Rarely will a person who doesn’t fall into one of these categories experience ear canal blockage due to excess earwax.
4. Cotton swabs should NOT be used to clean your ears
Speaking of cotton swabs, PLEASE DON’T USE THEM FOR EARWAX REMOVAL! What you are actually doing — instead of removing earwax — is wiping away wax in the outer 1/3 of the ear canal and pushing any remaining wax deeper into the ear canal. The most safe, effective way to remove problem cerumen is to visit a physician or hearing healthcare professional who can see into your ear canal then determine the best way to remove the earwax, if needed. Otherwise, simple hygiene practices, such as wiping the surface of the ear canal with a cloth while showering, should be sufficient to keep earwax from causing a problem.
5. Excessive earwax can be mistaken for hearing loss
Hearing loss is often blamed on earwax, but the actual problem is with the inner ear. Thousands of people who think they are experiencing hearing loss due to wax build-up are seen annually by hearing healthcare professionals when the true problem is hearing loss.
If you have ANY questions or concerns about the health of your ear or your hearing, the best course of action is to consult a physician and/or a hearing healthcare professional.
https://honiton-hearing.co.uk/wp-content/uploads/2021/02/facts-about-earwax.jpg375730adminhttps://honitonnew.leecurran.co.uk/wp-content/uploads/2018/03/honitonhearinglogo.pngadmin2021-02-02 13:57:232021-02-02 13:57:23Five things you should know about earwax
Primary progressive aphasia is a rare neurodegenerative condition characterised by prominent language problems that worsen over time. About 40% of people with the condition have underlying Alzheimer’s disease. But a new study has found that people with the condition may not develop the memory problems associated with Alzheimer’s disease. The study is published in the January 13, 2021, online issue of Neurology, the medical journal of the American Academy of Neurology (AAN). A summary of the research was also published on the AAN website.
“While we knew that the memories of people with primary progressive aphasia were not affected at first, we did not know if they maintained their memory functioning over years,” said study author M. Marsel Mesulam, MD, of Northwestern University Feinberg School of Medicine in Chicago and a Fellow of the American Academy of Neurology. “This has been difficult to determine because most memory tests rely on verbal skills that these people have lost or are losing.”
Honiton hearing centre
The study included 17 people with primary progressive aphasia associated with Alzheimer’s disease. They were compared to 14 people who had typical Alzheimer’s disease with memory loss.
Researchers tested memory skills of the people with primary progressive aphasia by showing them pictures of common objects. After waiting 10 minutes, they were shown the same pictures along with others and had to indicate whether they had seen the picture before. This test was given once and then again an average of 2.4 years later. The people with typical Alzheimer’s disease listened to a list of common words and were later given the same words along with others and asked to choose the ones they had heard before. They were tested once and then again an average of 1.7 years later.
Both groups also had tests of their language skills. Brain scans were taken of the people with primary progressive aphasia to look at how the disease was affecting their brains, especially in the areas related to memory.
The people with primary progressive aphasia had no decline in their memory skills when they took the tests a second time. At that point, they had been showing symptoms of the disorder for an average of six years. In contrast, their language skills declined significantly during the same period. For the people with typical Alzheimer’s disease, their verbal memory and language skills declined with equal severity during the study.
Exeter ear wax removal
Researchers had brain autopsies from eight of the people with primary progressive aphasia and all of the people with typical Alzheimer’s disease. The people with primary progressive aphasia had similar amounts of the plaques and tangles that are signs of Alzheimer’s disease as the people with typical Alzheimer’s, Mesulam said. Left sided asymmetry of brain shrinkage and a lower incidence of brain proteins known as ApoE4 and TDP-43 were identified as potential contributors to the preservation of memory in this rare type of Alzheimer’s disease.
“More research is needed to help us determine what factors allow these people to show this resilience of memory skills even in the face of considerable Alzheimer’s disease pathology in the brain,” Mesulam said.
Limitations of the study are the relatively small sample size and that autopsies were not available for all of the primary progressive aphasia cases.
Original Paper: Mesulam MM, Coventry C, Kuang A, et al. Memory resilience in Alzheimer’s disease with primary progressive aphasia. Neurology. 2020. DOI: https://doi.org/10.1212/WNL.0000000000011397.
Source: AAN, Neurology
https://honiton-hearing.co.uk/wp-content/uploads/2021/01/Honiton-ear-wax-removal.jpg417500adminhttps://honitonnew.leecurran.co.uk/wp-content/uploads/2018/03/honitonhearinglogo.pngadmin2021-01-25 12:54:122021-07-04 14:58:35Primary Progressive Aphasia Memory Loss Measured
Oticon Launches Oticon More at 2021 OticonNext Event
Oticon announced that over 5,000 hearing care professionals registered to join the company for its 2021 OticonNext “Discover More” Conference, the company’s “biggest ever launch event for a new product.” The live, virtual knowledge-sharing experience introduced participants to Oticon More, “the world’s first hearing aid with an on-board deep neural network.” This new hearing aid is said to build on Oticon’s “proven BrainHearing approach to deliver a full and precisely balanced sound scene that makes it easier for the brain to perform optimally.” Oticon President Gary Rosenblum and Oticon staff experts showed conference participants how Oticon More represents a “fundamentally new approach” to signal processing.
“Through the OticonNext Conference, we aimed to equip practitioners with the knowledge and tools they need to continue to bring life-changing technology to patients,” said Rosenblum. “Over the past decade, Oticon has pioneered new standards and advanced its portfolio of hearing solutions dramatically. From our newest addition, Oticon More, to our innovative power and pediatric solutions, we continue to offer hearing care professionals and their patients one of the industry’s most comprehensive portfolios of hearing technology.”
Rosenblum shared recent honors for the new hearing solution with conference participants. On January 11, the Consumer Electronics Association named Oticon More an honoree in the CES 2021 Innovation Awards in the Health & Wellness and Wearable Technologies categories. This is the fifth consecutive year that Oticon, Inc has been recognized by the international awards program that annually selects the best of the best in consumer electronics. The most recent awards bring to an even dozen the number of times Oticon has been honored by the CES InnovationAwards program.
Inspiration, Innovation, and Practice Support
Keynote speaker Dan Buettner, author of The Blue Zones: Lessons for Living Longer from the People Who’ve Lived the Longest, provided guidance on how technology like Oticon More contributes to health and long life by enabling patients to maintain vital connections to people and the world. A panel discussion addressed questions from the online audience on Oticon More’s technology innovations, including the new Polaris platform. Following the conference, hearing care professionals were invited to explore The Zone exhibit hall to learn more about the variety of clinical and business support available through Oticon and the company’s business partners.
Interactive Webisodes Continue Knowledge Sharing
The conference’s interactive virtual format extends beyond the launch event with a series of post-conference educational webisodes that build on the knowledge gained at OticonNext. The live interactive sessions take a deeper dive into the audiology of Oticon More and the new research that shows the brain needs access to all sounds—not just speech—in order to work in a natural way. Scheduled for February and March, the five webisodes each last approximately one hour and require prior registration.
Learn more about Oticon More and the entire portfolio of Oticon hearing solutions with BrainHearing technology at: www.Oticon.com/More.
Available at the Honiton hearing centre near Exeter Devon
Source: Oticon
Images: Oticon
https://honiton-hearing.co.uk/wp-content/uploads/2019/02/Honiton-Devon-ear-wax-removal-Exeter-Tiverton-Lyme-Bay.png640640adminhttps://honitonnew.leecurran.co.uk/wp-content/uploads/2018/03/honitonhearinglogo.pngadmin2021-01-20 10:44:382021-01-20 10:44:38Oticon hearing aids
Neurophysiologists at the University of Connecticut (UConn) have discovered a new drug that may prevent tinnitus and treat epilepsy by selectively affecting potassium channels in the brain. According to an article in the June 10, 2015 edition of The Journal of Neuroscience, Anastasios V. Tzingounis, PhD, and colleagues say that both tinnitus and epilepsy are caused by overly excitable cells that flood the brain with an overload of signals that can lead to seizures (epilepsy) or phantom ringing in the ears (tinnitus).
The authors report that roughly 65 million people worldwide are affected by epilepsy. While exact statistics on tinnitus are not easy to determine, the American Tinnutus Association estimates that two million people in the US suffer from disabling tinnitus.
Anastasios V. Tzingounis, PhD, University of Connecticut
According to Tzingounis and co-authors, the existing drugs available to treat epilepsy don’t always work and can have serious side effects. One of the more effective drugs, retigabine, helps open KCNQ potassium channels, which serve as the “brakes” that shut down the signaling of overly excited nerves. Retigabine, however, has terrible side effects and is usually only given to adults who don’t get relief from other epilepsy drugs. The side effects of retigabine include sleepiness, dizziness, problems with hearing and urination, and a disturbing tendency to turn patients’ skin and eyes blue.
In 2013, Tzingounis began collaborating with Thanos Tzounopoulos, PhD, a tinnitus expert at the University of Pittsburgh, to create a new drug candidate. The new drug, SF0034, was chemically identical to retigabine, but included an extra fluorine atom. Originally developed by SciFluor, the company wanted to know whether the compound had promise for treating epilepsy and tinnitus.
Thanos Tzounopoulos, PhD, University of Pittsburgh
Tzingounis and Tzounopoulos thought the drug had the potential to be much better than retigabine in treating both conditions. They first had to determine if SF0034 worked on KCNQ potassium channels the same way retigabine does, and if so, if it would be better or worse.
The co-authors explain in their article that KCNQ potassium channels are found in the initial segment of axons, long nerve fibers that reach out and almost touch other cells. The gap between the axon and the other cell is called a synapse. When the cell wants to signal to the axon, it floods the synapse with sodium ions to create an electrical potential. When that electrical potential goes on too long, or gets overactive, the KCNQ potassium channel kicks in. The result is that it opens, potassium ions flood out, and the sodium-induced electrical potential shuts down.
In some types of epilepsy, the KCNQ potassium channels have trouble opening and shutting down runaway electrical potentials in the nerve synapse. Retigabine helps them open. According to the authors, there are five different kinds of KCNQ potassium channels in the body, but only two are important in epilepsy and tinnitus: KCNQ2 and KCNQ3. The problem with retigabine is that it acts on other KCNQ potassium channels as well. That’s why it has so many unwanted side effects.
When testing SF0034 in neurons, the researchers found that it was more selective than retigabine. It appeared to open only KCNQ2 and KCNQ3 potassium channels, and to not affect the KCNQ 4 or 5 potassium channels. The research showed that SF0034 was more effective than retigabine at preventing seizures in animals, and it was also less toxic.
The results are promising, and SciFluor plans to start FDA trials with SF0034 to test its safety and efficacy in people. Treating epilepsy is the primary goal, but treating or preventing tinnitus is a secondary goal.
https://honiton-hearing.co.uk/wp-content/uploads/2019/03/Honiton-hearing-aids-Devon-2019.jpg360640adminhttps://honitonnew.leecurran.co.uk/wp-content/uploads/2018/03/honitonhearinglogo.pngadmin2021-01-09 15:16:472021-07-04 14:58:35New Drug Promises Relief from Tinnitus
A technology called functional near-infrared spectroscopy (fNIRS) can be used to objectively measure tinnitus, or ringing in the ears, according to a new study published November 18 in the open-access journal PLoS ONE by Mehrnaz Shoushtarian of The Bionics Institute, Australia, and colleagues. A summary of the study was published on the Science Daily website.
Tinnitus, the perception of a high-pitched ringing or buzzing in the ears, affects up to 20% of adults and, when severe, is associated with depression, cognitive dysfunction, and stress. Despite its wide prevalence, there has been no clinically used, objective way to determine the presence or severity of tinnitus.
In the new study, researchers turned to fNIRS, a non-invasive and non-radioactive imaging method which measures changes in blood oxygen levels within brain tissue. The team used fNIRS to track activity in areas of the brain’s cortex previously linked to tinnitus. They collected fNIRS data in the resting state and in response to auditory and visual stimuli in 25 people with chronic tinnitus and 21 controls matched for age and hearing loss. Participants also rated the severity of their tinnitus using the Tinnitus Handicap Inventory.
fNIRS revealed a statistically significant difference in the connectivity between areas of the brain in people with and without tinnitus. Moreover, the brain’s response to both visual and auditory stimuli was dampened among patients with tinnitus. When a machine learning approach was applied to the data, a program could differentiate patients with slight/mild tinnitus from those with moderate/severe tinnitus with an 87.32% accuracy. The authors conclude that fNIRS may be a feasible way to objectively assess tinnitus to assess new treatments or monitor the effectiveness of a patient’s treatment program.
The authors add: “Much like the sensation itself, how severe an individual’s tinnitus is has previously only been known to the person experiencing the condition. We have combined machine learning and non-invasive brain imaging to quantify the severity of tinnitus. Our ability to track the complex changes that tinnitus triggers in a sufferer’s brain is critical for the development of new treatments.”
Newly formed cochlear hair cells contain intricate hair bundles with many stereocilia (critical for sensing sound) and other components that are critical for proper function and neural transmission. Credit: Will McLean
An approach to regenerate inner ear sensory hair cells reportedly lays the groundwork for treating chronic noise-induced hearing loss by the company, Frequency Therapeutics, Woburn, Mass, and its co-founders who are drawing on research from Brigham and Women’s Hospital (BWH), Harvard Medical School, Mass Eye and Ear Infirmary, and Massachusetts Institute of Technology (MIT). In the February 21, 2017 edition of Cell Reports, the scientists describe a technique to grow large quantities of inner ear progenitor cells that convert into hair cells. The same techniques are said to show the ability to regenerate hair cells in the cochlea.
Hearing loss affects 360 million people worldwide according to the World Health Organization (WHO). Inner ear hair cells are responsible for detecting sound and helping to signal it to the brain. Loud sounds and toxic drugs can lead to death of the hair cells, which do not regenerate. Humans are born with only 15,000 sensory hair cells in each cochlea, which are susceptible to damage from exposure to loud noises and medications—leading to cell death and hearing loss over time.
According to a press release from Frequency Therapeutics, sufficient numbers of mammalian cochlear hair cells have not been able to be obtained to facilitate the development of therapeutic approaches for hearing loss. The new research built on previous work to control the growth of intestinal stem cells expressing the protein Lgr5 and targeted a different population of Lgr5 cells that were discovered to be the source of sensory hair cells in the cochlea during development (a subset of supporting cells or progenitors). The team successfully identified a protocol of small molecules to efficiently grow the cochlear progenitor cells into large colonies with a high capacity for differentiation into bona fide hair cells.
Jeff Karp, PhD
“The ability to regenerate hair cells within the inner ear already exists in nature,” said Jeff Karp, PhD, of BWH and Harvard Medical School in the press release. “Birds and amphibians are able to regenerate these cells throughout their lives, which provided the base for our inspiration to find similar pathways in mammals. With our collaborators at Mass Eye and Ear Infirmary, we were able to study a small molecule approach, that we developed at MIT and BWH, to expand progenitor cells from the mouse cochlea. We believe this technique represents a major advance for hearing loss research and will enable new physiological studies as well as genetic screens using drugs, siRNA, or gene overexpression.”
The research team first focused on optimizing the expansion of Lgr5 expressing cochlear progenitor cells. With the combination of a GSK3 inhibitor to activate the Wnt signaling pathway and a histone deacetylase (HDAC) inhibitor to activate gene transcription, the research team achieved a greater than 2000-fold expansion of cochlear supporting cells compared to previous approaches. This protocol was used successfully and with consistency to generate colonies of neonatal and adult murine cells, as well as primate and human progenitor cells. Furthermore, according to the researchers, the team achieved 60-fold enhancement of hair cell production from the progenitor cells compared to current methods.
The generation of new hair cells was achieved even in cochlear tissue that had been depleted of hair cells by exposure to an ototoxic antibiotic. Importantly, hair cells produced from the protocols exhibited the same physical features, gene expression, and functionality as typical cochlear hair cells, says Frequency Therapeutics.
“This work has opened an entire field of what we call Progenitor Cell Activation (PCA), which we believe has many regenerative applications beyond hearing loss, ranging from skin-related diseases and ocular ailments to gastrointestinal diseases and diabetes,” said Will McLean, PhD, co-founder and VP, Biology and Regenerative Medicine, at Frequency Therapeutics, and the lead author of the paper. “Furthermore, the approach creates a platform with potential to explore large populations of previously difficult-to-access progenitor cell types. Drug discovery for the inner ear was limited by the inability acquire enough primary cells to explore drug targets. This approach unlocks that ability for hearing research and a variety of other fields.”
“By using Progenitor Cell Activation to restore healthy tissue within the inner ear, we’re harnessing the body’s innate ability to heal itself,” said David Lucchino, co-founder, president and CEO of Frequency Therapeutics. “Frequency’s development of a disease modifying therapeutic that can be administered with a simple injection could have a profound effect on chronic noise-induced hearing loss, our lead indication, and we are rapidly advancing this program into human clinical trials within the next 18 months,” added Chris Loose, PhD, co-founder and CSO of the company.
Frequency Therapeutics was founded to translate what the company describes as breakthrough work in Progenitor Cell Activation (PCA) by its scientific founders, Robert Langer, ScD, and Jeff Karp, PhD, into new treatments where controlled tissue regeneration with locally delivered drugs could have profound therapeutic potential. The company has licensed foundational patents from the MIT and Partners Healthcare.
Hearing Review has published several articles on work involving Lrg5, including work involving a co-author of this study, Albert Edge, PhD, and related work on blocking the notch pathway.
Sources: Frequency Therapeutics; Brigham and Women’s Hospital; Cell Reports
https://honiton-hearing.co.uk/wp-content/uploads/2020/12/Cochlear-hair-cells.png6401280adminhttps://honitonnew.leecurran.co.uk/wp-content/uploads/2018/03/honitonhearinglogo.pngadmin2020-12-14 17:23:412021-07-04 14:58:35Study Shows Hair Cell Regrowth with New Drug
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
